|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000013831 |
|
Date of registration:
|
30/04/2014 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation
|
|
Scientific title:
|
Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation - Effect of inhaled corticosteroid therapy on pulmonary sarcoidosis |
|
Date of first enrolment:
|
2014/04/30 |
|
Target sample size:
|
40 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016140 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Toshio Suzuki |
|
Address:
|
1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan
Japan |
|
Telephone:
|
043-226-2800 |
|
Email:
|
toshiosuzuki@chiba-u.jp |
|
Affiliation:
|
Graduate School of Medicine, Chiba University, Chiba, Japan Department of Respirology |
|
|
Name:
|
Toshio Suzuki |
|
Address:
|
1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan
Japan |
|
Telephone:
|
043-226-2800 |
|
Email:
|
toshiosuzuki@chiba-u.jp |
|
Affiliation:
|
Graduate School of Medicine, Chiba University, Chiba, Japan Department of Respirology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: 1. patients with heart failure 2. patients with renal failure 3. patients with past hisotry of bronchial asthma 4. ex, or current smokers 5. patients with pulmonary disease except for pulmonary sarcoidosis 6. patients whose participations in this study are thought to be inappropriate.
Age minimum:
20years-old
Age maximum:
80years-old
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Pulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT.
|
|
Intervention(s)
|
|
inhaled ciclesonide (400maicrogram, twice daily, for three months)
|
|
Primary Outcome(s)
|
|
To evaluate the influence of inhaled ciclesonide (400maicrogram, twice daily, for three months) on pulmonary function tests, impulse oscillometry system (IOS) and HRCT of pulmonary sarcoidosis patients.
|
|
Source(s) of Monetary Support
|
|
self funding
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|